文献速递骨质疏松与钙磷/甲状旁腺

帕罗培特立帕肽治疗成人甲状旁腺功能减退症的患者报告结局:PaTH Forward试验扩展期

Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

PaTH Forward是一项2期临床试验,含4周随机双盲安慰剂对照期及至第266周的开放标签扩展期,评估帕罗培特立帕肽对慢性甲状旁腺功能减退症成人症状、日常功能与健康相关生活质量的影响。患者报告结局在第12周较基线显著改善,并持续至第110周,平均变化达到临床意义阈值,SF-36v2一般健康相关生活质量亦显著改善。

要点

  • 帕罗培特立帕肽显著改善疾病特异性症状及日常功能与健康感受,并持续至第110周。
  • 患者报告结局的平均变化达到临床意义阈值。
  • SF-36v2一般健康相关生活质量亦显著改善,各人口学特征间结果总体相似。

核心结论

  • 至第110周,帕罗培特立帕肽PTH替代治疗与疾病特异性症状、日常功能与健康感受及一般健康相关生活质量的显著改善相关。

研究设计与样本

  • PaTH Forward为2期临床试验,含4周随机双盲安慰剂对照期,随后为开放标签扩展期至试验第266周。
  • 患者报告结局在基线、第4、12、26、58周及此后每年至试验结束收集。
  • 采用甲状旁腺功能减退症患者体验量表(HPES)评估疾病特异性症状及对功能和健康感受的影响,SF-36v2评估一般健康相关生活质量。
  • 数据分析采用描述性统计与重复测量混合模型。

主要发现

  • 帕罗培特立帕肽治疗使疾病特异性症状及对日常功能与健康感受的影响在第12周较基线显著改善,并持续至第110周。
  • 患者报告结局的平均变化达到临床意义范围内患者内改善的阈值。
  • SF-36v2评分显示一般健康相关生活质量显著改善。
  • 各人口学与患者特征间结果总体相似。

临床怎么用

  • 对慢性甲状旁腺功能减退症成人,可考虑PTH替代治疗以改善症状、日常功能与生活质量。
  • 疗效评估可结合疾病特异性患者报告结局(HPES)与一般健康相关生活质量(SF-36v2)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Individuals with hypoparathyroidism experience a range of physical and cognitive symptoms and reduced quality of life (QoL) despite management with conventional therapy (active vitamin D and calcium). OBJECTIVE: This analysis investigated the long-term impact of parathyroid hormone (PTH) replacement therapy with palopegteriparatide (YORVIPATH®) on symptoms, daily functioning, and well-being in adults with chronic hypoparathyroidism. Associations between patient characteristics and changes in patient-reported outcomes (PROs) were also analyzed. METHODS: PaTH Forward was a phase 2 clinical trial of palopegteriparatide with a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension period lasting through trial week 266. PRO measures were collected at baseline, weeks 4, 12, 26, 58, and annually thereafter through the end of the trial. The Hypoparathyroidism Patient Experience Scales (HPES) assess disease-specific symptoms and impacts on functioning and well-being. The Short Form Health Survey (SF-36v2) measures general health-related QoL. Data were analyzed using descriptive statistics and Mixed Models for Repeated Measures. RESULTS: Palopegteriparatide treatment demonstrated significant improvements from baseline in disease-specific symptoms and impacts on daily functioning and well-being at week 12, which were sustained through week 110. Mean changes in PROs met thresholds for clinically meaningful within-patient improvement. Significant improvements in general health-related QoL were also shown in SF-36v2 scores. Results were generally similar across demographics and patient characteristics. CONCLUSION: Through week 110 of the PaTH Forward trial, PTH replacement therapy with palopegteriparatide was associated with significant improvements in disease-specific symptoms and impacts on daily functioning and well-being, as well as general health-related QoL.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rubin M, Palermo A, Vokes T, et al. Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. J Clin Endocrinol Metab. 2026. PMID: 41365829. doi:10.1210/clinem/dgaf653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。